Edwards Lifesciences (EW) Q3 2026 Earnings Call: Guidance and Outlook
Management updated its full-year 2026 outlook, raising total company sales growth guidance and adjusted EPS expectations based on strong third-quarter performance and underlying business momentum.
About Edwards Lifesciences. Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring.
$1.67 billion to $1.75 billion for the fourth quarter of 2026.
Adjusted EPS
$0.61 to $0.69 for the fourth quarter of 2026.
Annual guidance
Total sales growth
Approximately 11.5% for the full year 2026.
TAVR sales growth
9% to 9.5% for the full year 2026.
TMTT sales
$780 million to $790 million for the full year 2026.
Adjusted EPS
$2.97 to $3.05 for the full year 2026.
Outlook
Long-term TAVR growth
Expectation of durable mid- to high single-digit growth for the SAPIEN platform over the long term supported by clinical evidence and modernized NCD policies.
TMTT revenue target
Pathways supporting $2 billion in TMTT revenue in 2030.
Operating margin
Expected to be at the high end of the original 28% to 29% guidance for 2026, with 50 to 100 basis points of underlying operating margin expansion planned beyond 2026.
Tax rate
Expected to be at the high end of the 16% to 19% guidance range.
Dombey's summary of the Edwards Lifesciences Q3 2026 earnings call held Nov 4, 2026, written from the call itself. Every figure on this page was checked against what was said on the call, and quoted lines are management's own words; we do not add estimates or prices. The tone score is our read of management's wording, guidance and answers. Check figures against the company's SEC filings before acting. This is research, not investment advice.
